The m-TORC1 inhibitor Sirolimus increases the effectiveness of Photodynamic therapy in the treatment of cutaneous Squamous Cell Carcinoma, impairing NRF2 antioxidant signaling.
NF-E2-Related Factor 2
/ metabolism
Photochemotherapy
/ methods
Animals
Mice
Sirolimus
/ pharmacology
Humans
Carcinoma, Squamous Cell
/ drug therapy
Skin Neoplasms
/ metabolism
Cell Line, Tumor
Signal Transduction
/ drug effects
Mechanistic Target of Rapamycin Complex 1
/ metabolism
Aminolevulinic Acid
/ therapeutic use
Antioxidants
/ pharmacology
Reactive Oxygen Species
/ metabolism
Female
Antioxidant Response
Cutaneous Squamous Cell Carcinoma
Photodynamic Therapy
Rapamycin
Tumor Resistance
Journal
International journal of biological sciences
ISSN: 1449-2288
Titre abrégé: Int J Biol Sci
Pays: Australia
ID NLM: 101235568
Informations de publication
Date de publication:
2024
2024
Historique:
received:
31
01
2024
accepted:
17
06
2024
medline:
9
9
2024
pubmed:
9
9
2024
entrez:
9
9
2024
Statut:
epublish
Résumé
Squamous Cell Carcinoma (SCC) is a subtype of Non-Melanoma Skin Cancer, the most common group of malignancies worldwide. Photodynamic therapy (PDT) is a non-invasive treatment approved for specific subtypes of SCC. Some malignancies resist PDT, forming more aggressive tumors and multiple relapses. Thus, new approaches aimed at optimizing the response to PDT are needed. The mTORC1 inhibitor rapamycin, also known as Sirolimus (SRL), interferes with protein synthesis and cell metabolism. The use of SRL as an immunosuppressant is associated to lower rates of SCC in kidney-transplanted patients, which are frequently affected by this pathology. We have evaluated SRL pre-treatment efficacy to enhance the damage induced by PDT with Methyl 5-aminolevulinate in two different cutaneous SCC established cell lines (SCC13 and A431)
Identifiants
pubmed: 39247827
doi: 10.7150/ijbs.94883
pii: ijbsv20p4238
pmc: PMC11379070
doi:
Substances chimiques
NF-E2-Related Factor 2
0
Sirolimus
W36ZG6FT64
Mechanistic Target of Rapamycin Complex 1
EC 2.7.11.1
Aminolevulinic Acid
88755TAZ87
Antioxidants
0
Reactive Oxygen Species
0
NFE2L2 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4238-4257Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.